EG 427

Philippe Chambon, M.D., Ph.D., CEO

April 13 | 9:30am | Dark Horse Consulting Ballroom 

Paris, France


EG 427 develops next-generation gene therapies specifically targeted to underlying mechanism of action, at the local level, in order to address major chronic diseases where it matters and in a safe and cost-effective manner. Non-replicative Herpes Simplex Virus 1 (nrHSV-1) derived vectors are a powerful tool to achieve highly selective, safe, and durable expression of transgenes addressing localized diseases in the peripheral nervous system and beyond.

By using this website you agree to accept our Privacy Policy and Terms & Conditions